HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Syndia v. Gillette

This article was originally published in The Rose Sheet

Executive Summary

Gillette ordered to pay Syndia $10 mil. in damages June 14 by jury in Chicago federal court in patent infringement case. Gillette's "diamond-like carbon"-coated razor blades used in Mach3, Mach3 Turbo and Venus razors found to infringe patents owned by Syndia, Chicago company maintains. Damages and injunctive relief for any future infringement have yet to be determined, Syndia adds, noting it intends to file for injunctive relief "barring future sales of March3, Turbo and Venus." Gillette said the ruling will have no material impact on business and does not prevent the firm from manufacturing any of its blades or razors. "Gillette also is prepared to appeal this matter to the Federal Circuit Court of Appeals in Washington, D.C. if that should prove necessary," company adds...

You may also be interested in...

Industry Delighted By ‘Fixed’ USMCA

Industry associations in the US and Canada have welcomed revisions to the proposed US-Mexico-Canada trade agreement that remove potentially damaging provisions around biologic data exclusivity and include measures favorable to generics, including incentives for generic competition.

NeuClone’s Trastuzumab Trial Succeeds

NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.

EMA Prepares Approval Verdict On Beovu, Idhifa, Recarbrio

Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts